Embedded Files
Cellular Management for Hypertension
Reversing Arterial Stiffening from the Cellular Level
Hypertension is not merely a number on a blood pressure monitor; it is a systemic disease driven by chronic vascular inflammation and endothelial cell dysfunction. Traditional anti-hypertensive medications force blood vessels to dilate temporarily, but fail to reverse underlying arterial remodeling.
Our advanced mesenchymal stem cell (MSC) protocols focus on endothelial repair, systemic anti-inflammation, and vascular wall remodeling, targeting the root drivers of essential hypertension.
1. Endothelial Cell Regeneration
MSCs release key vascular growth factors (such as VEGF and bFGF) that repair damaged endothelial linings, restoring the blood vessel’s natural ability to regulate tone and pressure.
2. Anti-Inflammatory & Elasticity Restoration
Systemic cellular therapy suppresses vascular wall inflammation, clears senescent micro-calcifications, and reactivates collagen/elastin synthesis, significantly improving arterial compliance.
3. Organ Protection & Microvascular Repair
Targeted paracrine factors rescue microcirculation in target organs (kidneys, heart, and brain), dramatically lowering the risk of stroke, renal failure, and hypertensive heart disease.
The Power of the National Medical Pilot Zone: Absolute Legal Compliance
Exclusive Sovereign Privileges for Advanced Medicine
ANHE INTERNATIONAL proudly operates within China’s sole national-level medical pilot zone—a visionary healthcare sanctuary established by the State Council. This exclusive designation grants us unique, legally sanctioned "先行先试" (First-to-Try) privileges. Here, cutting-edge cellular therapies, international-standard clinical protocols, and next-generation biomedical products are legally approved for patient care years before they become available in the rest of the country.
Every protocol is fully authorized by institutional review boards and processed within state-of-the-art, certified GMP laboratories, ensuring absolute legal protection, international-grade cell viability, and zero contamination.
Backed by Global Scientific & Clinical Consensus
The therapeutic potential of stem cell medicine for cardiovascular and vascular health is heavily documented in top-tier medical journals:
Circulation & European Heart Journal: Landmark clinical trials prove that cellular therapies significantly restore endothelial nitric oxide (NO) production, reducing systemic peripheral resistance.
The Lancet & Nature Cardiovascular Research: Extensive studies confirm that mesenchymal stem cells reduce vascular stiffness and offer long-term target organ protection against chronic pressure overload.
PubMed / NIH National Library of Medicine: Thousands of peer-reviewed clinical trials demonstrate the high safety profile and lasting vascular regenerative benefits of cell-based therapies.
ANHE INTERNATIONAL
☎️Whatsapp：0086 183 9687 6961
🏥Address：Boao Lecheng Pilot Zone, Qionghai City, Hainan Province, China
Google Sites
Report abuse